Fig. 4From: First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysisCR, PR and SD (a The meta-analysis of four trials showed a higher complete response in the cetuximab than bevacizumab group). b The partial response was not significantly different in both groups. 4c: bevacizumab group was associated with more stable disease)Back to article page